Status:
COMPLETED
Circulating P3NP and Cardiovascular Events in Hemodialysis Patients
Lead Sponsor:
Toujinkai Hospital
Conditions:
Cardiovascular Events
Cardiac Fibrosis
Eligibility:
All Genders
Brief Summary
This study evaluates whether circulating levels of aminoterminal propeptide of type III procollagen (PIIINP) can predict the cardiovascular events in hemodialysis patients.
Detailed Description
Type III collagen abundantly exists in the cardiovascular system including the aorta and heart. The aminoterminal propeptide of type III procollagen (PIIINP) is an extension peptide of type III procol...
Eligibility Criteria
Inclusion
- End-stage kidney disease patients who had been undergoing maintenance hemodialysis over one year in Toujinkai Hospital at the point of January 1, 2005
Exclusion
- Histories of coronary events and/or interventions
- Congestive heart failure of New York Heart Association grades III to IV
- Moderate or worse valvular heart disease
- Permanent pacemaker implantation
- Idiopathic cardiomyopathy
- Chronic obstructive pulmonary disease
- Malignancy
- Acute hepatitis, chronic hepatitis, or liver cirrhosis including carrier of hepatitis virus
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2005
Estimated Enrollment :
244 Patients enrolled
Trial Details
Trial ID
NCT03391128
Start Date
January 1 2005
End Date
January 31 2005
Last Update
January 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toujinkai Hospital
Kyoto, Japan, 612-8026